Congenital hypothyroidism screening in the West Bank: a test case for screening in developing regions

J Sack1, I Feldman, I Kaiserman

  • 1Department of Pediatrics, Sheba Medical Center, Tel Hashomer, Israel.

Hormone Research
|October 8, 1998
PubMed

Insights

Congenital hypothyroidism (CH) screening in the West Bank is feasible despite challenges. This program successfully screened infants up to one month old, detecting CH at rates higher than industrialized nations.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Public Health

Background:

  • Neonatal screening for congenital hypothyroidism (CH) is crucial for early intervention.
  • Implementing CH screening in the West Bank faced logistical and political challenges, including home births and early hospital discharges.

Purpose of the Study:

  • To assess the feasibility and effectiveness of a CH screening program in the West Bank.
  • To determine the incidence of CH in the Arab population of the West Bank and East Jerusalem.

Main Methods:

  • A modified screening protocol prioritizing thyroid-stimulating hormone (TSH) testing was used to reduce recall rates.
  • Infants were targeted for screening at maternal and child health centers before one month of age, with 64% sampled within the first week.

Main Results:

  • From June 1990 to February 1994, 49,694 infants in the West Bank showed an incidence of CH of 1:2,070 (24 cases).
  • From January 1987 to February 1994, 28,938 infants in East Jerusalem showed an incidence of CH of 1:1,447 (20 cases).
  • Incidence rates in the West Bank and East Jerusalem were higher than in industrialized countries, potentially due to consanguinity and environmental factors.

Conclusions:

  • Congenital hypothyroidism screening is achievable in the West Bank, even with logistical and political hurdles.
  • Screening infants up to one month old allows for timely and effective treatment, establishing a baseline for future programs.